Steigerwald Gordon & Koch’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.35M | Hold |
2,796
| – | – | 0.33% | 49 |
|
|
2026
Q1 | $2.57M | Sell |
2,796
-18
| -0.6% | -$18.2K | 0.26% | 56 |
|
|
2025
Q4 | $3.02M | Buy |
2,814
+44
| +2% | +$42.1K | 0.29% | 55 |
|
|
2025
Q3 | $2.11M | Sell |
2,770
-178
| -6% | -$132K | 0.2% | 59 |
|
|
2025
Q2 | $2.3M | Sell |
2,948
-145
| -5% | -$113K | 0.24% | 52 |
|
|
2025
Q1 | $2.55M | Sell |
3,093
-2
| -0.1% | -$1.66K | 0.29% | 50 |
|
|
2024
Q4 | $2.39M | Sell |
3,095
-37
| -1% | -$30.6K | 0.27% | 50 |
|
|
2024
Q3 | $2.78M | Buy |
3,132
+13
| +0.4% | +$11.7K | 0.3% | 48 |
|
|
2024
Q2 | $2.82M | Sell |
3,119
-53
| -2% | -$42.4K | 0.34% | 48 |
|
|
2024
Q1 | $2.47M | Sell |
3,172
-255
| -7% | -$181K | 0.31% | 48 |
|
|
2023
Q4 | $2M | Buy |
3,427
+175
| +5% | +$102K | 0.27% | 48 |
|
|
2023
Q3 | $1.75M | Sell |
3,252
-50
| -2% | -$25.8K | 0.27% | 47 |
|
|
2023
Q2 | $1.55M | Buy |
3,302
+1
| +0% | +$419 | 0.23% | 46 |
|
|
2023
Q1 | $1.13M | Sell |
3,301
-255
| -7% | -$86K | 0.17% | 51 |
|
|
2022
Q4 | $1.3M | Sell |
3,556
-167
| -4% | -$59.2K | 0.21% | 50 |
|
|
2022
Q3 | $1.2M | Sell |
3,723
-46
| -1% | -$14.6K | 0.22% | 50 |
|
|
2022
Q2 | $1.22M | Buy |
3,769
+603
| +19% | +$181K | 0.21% | 52 |
|
|
2022
Q1 | $907K | Sell |
3,166
-613
| -16% | -$158K | 0.14% | 61 |
|
|
2021
Q4 | $1.04M | Hold |
3,779
| – | – | 0.16% | 60 |
|
|
2021
Q3 | $873K | Sell |
3,779
-70
| -2% | -$17.3K | 0.14% | 59 |
|
|
2021
Q2 | $884K | Hold |
3,849
| – | – | 0.15% | 58 |
|
|
2021
Q1 | $719K | Sell |
3,849
-278
| -7% | -$54.4K | 0.13% | 62 |
|
|
2020
Q4 | $697K | Buy |
4,127
+48
| +1% | +$7.17K | 0.14% | 60 |
|
|
2020
Q3 | $604K | Sell |
4,079
-4
| -0.1% | -$619 | 0.14% | 58 |
|
|
2020
Q2 | $670K | Hold |
4,083
| – | – | 0.18% | 57 |
|
|
2020
Q1 | $566K | Buy |
4,083
+778
| +24% | +$107K | 0.19% | 57 |
|
|
2019
Q4 | $434K | Buy |
3,305
+1,255
| +61% | +$145K | 0.1% | 67 |
|
|
2019
Q3 | $229K | Sell |
2,050
-24
| -1% | -$2.67K | 0.06% | 77 |
|
|
2019
Q2 | $230K | Sell |
2,074
-500
| -19% | -$58.9K | 0.06% | 76 |
|
|
2019
Q1 | $334K | Sell |
2,574
-426
| -14% | -$51.8K | 0.09% | 64 |
|
|
2018
Q4 | $347K | Hold |
3,000
| – | – | 0.1% | 63 |
|
|
2018
Q3 | $322K | Hold |
3,000
| – | – | 0.08% | 72 |
|
|
2018
Q2 | $256K | Sell |
3,000
-300
| -9% | -$24.6K | 0.07% | 76 |
|
|
2018
Q1 | $255K | Sell |
3,300
-400
| -11% | -$32.2K | 0.07% | 73 |
|
|
2017
Q4 | $313K | Buy |
+3,700
| New | +$315K | 0.09% | 65 |
|
Other funds holding LLY
SC
ONB
GIM
Steigerwald Gordon & Koch's LLY Position: Q2 2026 in Review
Steigerwald Gordon & Koch held its Eli Lilly (LLY) position steady in Q2 2026 at 2,796 shares worth $3.35M. The position accounts for 0.33% of the portfolio, ranked #49.
Steigerwald Gordon & Koch first reported a position in LLY in Q4 2017 and has held it in 35 quarters since. 1,842 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Steigerwald Gordon & Koch held 2,796 shares of Eli Lilly worth $3.35M as of Q2 2026.
- Steigerwald Gordon & Koch left its Eli Lilly share count unchanged in Q2 2026.
- Eli Lilly made up 0.33% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #49 holding.
- Steigerwald Gordon & Koch first reported a position in Eli Lilly in Q4 2017 and has held it in 35 quarters since.
- 1,842 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.